

Supplementary Table 1 Plasma ethanol level, plasma alanine aminotransferase, plasma aspartate aminotransferase and body weight on day 0 after 4-week diet administration or before treatment initiation, mean $\pm$ SEM

Treatment	Plasma ethanol (mg/dL)	Plasma ALT (U/L)	Plasma AST (U/L)	Body weight (g)
Normal control	9.6 $\pm$ 1.4	26.6 $\pm$ 2.1	48.7 $\pm$ 2.3	26.5 $\pm$ 0.5
Disease control	588.8 $\pm$ 22.5	59.4 $\pm$ 4.4	101.1 $\pm$ 16.3	23.2 $\pm$ 0.6
Saroglitazar (0.4 mg/kg, PO)	582.0 $\pm$ 18.1	59.2 $\pm$ 3.5	99.4 $\pm$ 11.5	22.6 $\pm$ 0.5
Saroglitazar (0.8 mg/kg, PO)	588.5 $\pm$ 25.4	63.2 $\pm$ 4.5	92.3 $\pm$ 7.7	22.5 $\pm$ 0.5
UDCA (250 mg/kg, PO, BID)	581.7 $\pm$ 22.9	62.5 $\pm$ 6.2	101.7 $\pm$ 9.3	23.4 $\pm$ 0.5

Data are presented as mean $\pm$ SEM ($n = 8-9$). ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BID: Twice daily; PO: Orally; UDCA: Ursodeoxycholic acid.

Supplementary Table 2 Detail primer sequences used for hepatic gene expression in quantitative polymerase chain reaction analysis

Primer	Sequence	Accession number
<i>CYP2E1</i>	Forward: 5'-CTGAGATATGGGCTCCTGATTC-3' Reverse: 5'-ATCTCATGCACTACAGCGTC-3'	NM_021282.3
<i>Adh1</i>	Forward: 5'-GGAGGGGTGGACTTTTCGTT-3' Reverse: 5'-TACGACGACGCTTACACCAC-3'	NM_007409.3
<i>Aldh2</i>	Forward: 5'-AGACCATCGAGGAGGTTGTG-3' Reverse: 5'-CCCCAAACACATCGTAGCAG-3'	NM_009656.4
β -actin	Forward: 5'-CACTGTCGAGTCGCGTCC-3' Reverse: 5'-TCATCCATGGCGAACTGGTG-3'	NM_007393.5

Supplementary Table 3 Effect of saroglitazar on plasma inflammatory marker monocyte chemoattractant protein-1, oxidative stress marker liver malondialdehyde level, fibrosis marker- total collagen level after 4-week drug

administration ($n = 8-9$)

Treatment	Plasma acetaldehyde (μm) level 2 hours post ethanol binge	Plasma MCP-1 (ng/mL)	Liver MDA ($\mu\text{m}/\text{gm}$ of tissue)	Liver total collagen (ng/gm)
Disease control	0.59 ± 0.05	17.3 ± 1.3	21.7 ± 2.6	331.4 ± 24.1
Saroglitazar (0.4 mg/kg, PO)	0.51 ± 0.01	19.8 ± 1.4	21.3 ± 1.6	323.9 ± 24.7
Saroglitazar (0.8 mg/kg, PO)	0.64 ± 0.04	17.2 ± 1.5	24.7 ± 1.6	309.3 ± 24.1
UDCA (250 mg/kg, PO, BID)	0.69 ± 0.04	14.7 ± 0.9	108.6 ± 6.1	369.5 ± 25.9

Data are presented as mean $\pm$ SEM ($n = 8-9$). UDCA: Ursodeoxycholic acid; BID: Twice daily; PO: Orally; MDA: malondialdehyde; MCP-1: Monocyte chemoattractant protein-1;

Supplementary Table 4 Representative liver histology showing the effect of saroglitazar evaluated by hematoxylin and eosin and Sirius Red staining after 4 weeks of treatment ($n = 8-9$ per group)

Treatment	Inflammation	Fibrosis score by HE staining	Fibrosis score by Sirius Red staining
Normal control	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
Disease control	0.0 ± 0.0	0.0 ± 0.0	0.0 ± 0.0
Saroglitazar (0.4 mg/kg, PO)	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0
Saroglitazar (0.8 mg/kg, PO)	0.3 ± 0.2	0.0 ± 0.0	0.0 ± 0.0
UDCA (250 mg/kg, PO, BID)	0.2 ± 0.1	0.0 ± 0.0	0.0 ± 0.0

Data are presented as mean $\pm$ SEM ($n = 8-9$). HE: Hematoxylin and eosin; UDCA: Ursodeoxycholic acid; BID: Twice daily; PO: Orally.